NSC636819
CAS No. : 1618672-71-1
| Size | Price | Stock |
|---|---|---|
| 1mg | $155 | In-stock |
| 5mg | $465 | In-stock |
| 10mg | $744 | In-stock |
| 50 mg | Get quote | |
| 100 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-110154 |
| M.Wt: | 510.15 |
| Formula: | C22H12Cl4N2O4 |
| Purity: | >98 % |
| Solubility: | DMSO : 5.1015 mg/mL (ultrasonic;warming) |
NSC636819 is a competitive and selective inhibitor of KDM4A/KDM4B. KDM4A/KDM4B are potential progression factors for prostate cancer. NSC636819 has the potential for the research of cancer diseases, especially prostate cancer[1][2].
In Vitro:NSC636819 (compound 4) targets KDM4A and KDM4B with Ki of 5.5 μM and 3.0 μM, respectively[1].
NSC636819 (100 μM; 30 min) inhibits the demethylation activity of KDM4A and KDM4B and significantly reduces the level of H3K9me3 in LNCaP cells[1].NSC636819 (5-20 μM; 3 d) is cytotoxic (LNCaP IC50 = 16.5 μM) and induces apoptosis in LNCaP cells[1].NSC636819 (C-4) (10-20 μM; 2 d) strongly induces the expression of both TRAIL and its receptor DR5 selectively (mRNA and protein) in both TRAIL-sensitive (Calu-6 and MDA-MB231) and TRAIL-resistant cancer cells (A549 and H1299)[2].
In Vivo:NSC636819 (C-4) (20 or 40 mg/kg; ip; 5 times a week; 4 weeks) strongly suppresses A549 tumor growth and sensitizes tumors to TRAIL-inducer ONC201 in mouse model[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- NSC636819
- Cat. No.:
- HY-110154
- Quantity:
Your information is safe with us.